MHC Expression Predicts Checkpoint Blockade Response.
MHC expression may affect response to immune checkpoint inhibitors in patients with advanced melanoma. In a recent retrospective analysis, patients with low MHC class I expression responded to a PD-1 inhibitor, but were less likely to respond to a CTLA4 inhibitor than patients with higher MHC class I expression.